SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA
The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear κB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to pituitary prolactinoma. We recruited 46 premenopausal femal...
Gespeichert in:
| Veröffentlicht in: | Endocrine practice 2017-03, Vol.23 (3), p.266-270 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 270 |
|---|---|
| container_issue | 3 |
| container_start_page | 266 |
| container_title | Endocrine practice |
| container_volume | 23 |
| creator | Arslan, Muyesser Sayki Sahin, Mustafa Karakose, Melia Tutal, Esra Topaloglu, Oya Ucan, Bekir Demirci, Taner Caliskan, Mustafa Ozdemir, Seyda Ozbek, Mustafa Cakal, Erman |
| description | The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear κB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to pituitary prolactinoma.
We recruited 46 premenopausal female patients with prolactinoma and age and sex-matched healthy controls (Group 3, n = 20) for this cross-sectional study. Prolactinoma patients were divided into 2 groups as patients newly diagnosed (Group 1, n = 26) and those under cabergoline treatment (Group 2, n = 20). Anthropometric and metabolic variables; hormonal profiles; and osteocalcin, deoxypyridinoline (DOP), and bone mineral density measurements were performed for all participants. FGF-23, OPG, and RANKL levels were analyzed in all groups.
FGF-23, OPG, calcium, phosphorus, and parathormone levels were similar between all groups despite significantly higher levels in the control group in terms of vitamin D and RANKL levels than in patients. Bone loss was found more in Group 2, particularly observed in Z scores of femur and spinal bone (P |
| doi_str_mv | 10.4158/EP161440.OR |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1878752301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4320980475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-7f97c55c5ab0906241b8f261247fd85eb459f3a6a74626e23bd49bd6cde762333</originalsourceid><addsrcrecordid>eNo9kctOwzAURC0EorxW7JElljTgV2Jn6QYnjQhx5KTALspTogJaErrgO_hhXNGyurM4MyPdAeASo1uGXXGnMuxhxtCtNgfgBPuUOYQhemi1S5EjfPwyAafjuESIIB-LYzAhXDCfCn4CfnJlFo8wUU8qyaEOYRjPjJ4lMi9gZPRzMYehDAptHEKnUOeF0pnRhYqUidMplOk9NCpQmSWg5eInuVU2J10EiZJm54YPMssknMEkjraeOIWZLGKVFjl8jm2JDU22_lQ_ynNw1FdvY3exu2dgEaoimDuJjuJAJk5DMf9yeO_zxnUbt6qRjzzCcC164mHCeN8Kt6uZ6_e08irOPOJ1hNYt8-vWa9qOe4RSegau_3LXw-pz041f5XK1GT5sZYkFF9wlFGFL3fxRzbAax6Hry_Xw-l4N3yVG5XaAcj9AqY2lr3aZm_q9a__Z_cfpL7fac54</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1878752301</pqid></control><display><type>article</type><title>SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Arslan, Muyesser Sayki ; Sahin, Mustafa ; Karakose, Melia ; Tutal, Esra ; Topaloglu, Oya ; Ucan, Bekir ; Demirci, Taner ; Caliskan, Mustafa ; Ozdemir, Seyda ; Ozbek, Mustafa ; Cakal, Erman</creator><creatorcontrib>Arslan, Muyesser Sayki ; Sahin, Mustafa ; Karakose, Melia ; Tutal, Esra ; Topaloglu, Oya ; Ucan, Bekir ; Demirci, Taner ; Caliskan, Mustafa ; Ozdemir, Seyda ; Ozbek, Mustafa ; Cakal, Erman</creatorcontrib><description>The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear κB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to pituitary prolactinoma.
We recruited 46 premenopausal female patients with prolactinoma and age and sex-matched healthy controls (Group 3, n = 20) for this cross-sectional study. Prolactinoma patients were divided into 2 groups as patients newly diagnosed (Group 1, n = 26) and those under cabergoline treatment (Group 2, n = 20). Anthropometric and metabolic variables; hormonal profiles; and osteocalcin, deoxypyridinoline (DOP), and bone mineral density measurements were performed for all participants. FGF-23, OPG, and RANKL levels were analyzed in all groups.
FGF-23, OPG, calcium, phosphorus, and parathormone levels were similar between all groups despite significantly higher levels in the control group in terms of vitamin D and RANKL levels than in patients. Bone loss was found more in Group 2, particularly observed in Z scores of femur and spinal bone (P<.05). Correlation analysis revealed a negative correlation between FGF-23 and femur neck T score (r = -0.0433, P = .05) in patients with active prolactinoma. A positive correlation was also observed between parameters of DOP and OPG (r = 0.673, P = .02). In patients with remission there were a negative correlation between prolactin and luteinizing hormone (r = -600, P = .08). Additionally, a negative correlation was found between osteocalcin and osteoprotegerin in patients in remission (r = -0.73, P = .01).
Our data indicated that FGF-23 and OPG levels do not play a critical role on the development of bone decrease in patients with hyperprolactinemia. However, further prospective studies in larger numbers of participants should be designed to clarify this issue.
BFP = body fat percentage BMD = bone mineral density BMI = body mass index CV = coefficient of variation DOP = deoxypyridinoline ELISA = enzyme-linked immunosorbent assay FGF-23 = fibroblast growth factor-23 HOMA-IR = homeostatic model assessment of insulin resistance OPG = osteoprotegerin RANKL = receptor activator nuclear κB ligand.</description><identifier>ISSN: 1530-891X</identifier><identifier>EISSN: 1934-2403</identifier><identifier>DOI: 10.4158/EP161440.OR</identifier><identifier>PMID: 27849387</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Adult ; Amino Acids - blood ; Antineoplastic Agents - therapeutic use ; Biomarkers, Tumor - blood ; Bone Density ; Cabergoline ; Cross-Sectional Studies ; Ergolines - therapeutic use ; Female ; Fibroblast Growth Factors - blood ; Humans ; Middle Aged ; Osteocalcin - blood ; Osteoprotegerin - blood ; Pituitary Neoplasms - blood ; Pituitary Neoplasms - drug therapy ; Prolactinoma - blood ; Prolactinoma - drug therapy ; Prospective Studies ; RANK Ligand - blood ; Receptor Activator of Nuclear Factor-kappa B - blood ; Vitamin D - blood</subject><ispartof>Endocrine practice, 2017-03, Vol.23 (3), p.266-270</ispartof><rights>Copyright Allen Press Publishing Services Mar 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-7f97c55c5ab0906241b8f261247fd85eb459f3a6a74626e23bd49bd6cde762333</citedby><cites>FETCH-LOGICAL-c317t-7f97c55c5ab0906241b8f261247fd85eb459f3a6a74626e23bd49bd6cde762333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1878752301?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,782,786,27933,27934,64394,64398,72478</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27849387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arslan, Muyesser Sayki</creatorcontrib><creatorcontrib>Sahin, Mustafa</creatorcontrib><creatorcontrib>Karakose, Melia</creatorcontrib><creatorcontrib>Tutal, Esra</creatorcontrib><creatorcontrib>Topaloglu, Oya</creatorcontrib><creatorcontrib>Ucan, Bekir</creatorcontrib><creatorcontrib>Demirci, Taner</creatorcontrib><creatorcontrib>Caliskan, Mustafa</creatorcontrib><creatorcontrib>Ozdemir, Seyda</creatorcontrib><creatorcontrib>Ozbek, Mustafa</creatorcontrib><creatorcontrib>Cakal, Erman</creatorcontrib><title>SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA</title><title>Endocrine practice</title><addtitle>Endocr Pract</addtitle><description>The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear κB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to pituitary prolactinoma.
We recruited 46 premenopausal female patients with prolactinoma and age and sex-matched healthy controls (Group 3, n = 20) for this cross-sectional study. Prolactinoma patients were divided into 2 groups as patients newly diagnosed (Group 1, n = 26) and those under cabergoline treatment (Group 2, n = 20). Anthropometric and metabolic variables; hormonal profiles; and osteocalcin, deoxypyridinoline (DOP), and bone mineral density measurements were performed for all participants. FGF-23, OPG, and RANKL levels were analyzed in all groups.
FGF-23, OPG, calcium, phosphorus, and parathormone levels were similar between all groups despite significantly higher levels in the control group in terms of vitamin D and RANKL levels than in patients. Bone loss was found more in Group 2, particularly observed in Z scores of femur and spinal bone (P<.05). Correlation analysis revealed a negative correlation between FGF-23 and femur neck T score (r = -0.0433, P = .05) in patients with active prolactinoma. A positive correlation was also observed between parameters of DOP and OPG (r = 0.673, P = .02). In patients with remission there were a negative correlation between prolactin and luteinizing hormone (r = -600, P = .08). Additionally, a negative correlation was found between osteocalcin and osteoprotegerin in patients in remission (r = -0.73, P = .01).
Our data indicated that FGF-23 and OPG levels do not play a critical role on the development of bone decrease in patients with hyperprolactinemia. However, further prospective studies in larger numbers of participants should be designed to clarify this issue.
BFP = body fat percentage BMD = bone mineral density BMI = body mass index CV = coefficient of variation DOP = deoxypyridinoline ELISA = enzyme-linked immunosorbent assay FGF-23 = fibroblast growth factor-23 HOMA-IR = homeostatic model assessment of insulin resistance OPG = osteoprotegerin RANKL = receptor activator nuclear κB ligand.</description><subject>Adult</subject><subject>Amino Acids - blood</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomarkers, Tumor - blood</subject><subject>Bone Density</subject><subject>Cabergoline</subject><subject>Cross-Sectional Studies</subject><subject>Ergolines - therapeutic use</subject><subject>Female</subject><subject>Fibroblast Growth Factors - blood</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Osteocalcin - blood</subject><subject>Osteoprotegerin - blood</subject><subject>Pituitary Neoplasms - blood</subject><subject>Pituitary Neoplasms - drug therapy</subject><subject>Prolactinoma - blood</subject><subject>Prolactinoma - drug therapy</subject><subject>Prospective Studies</subject><subject>RANK Ligand - blood</subject><subject>Receptor Activator of Nuclear Factor-kappa B - blood</subject><subject>Vitamin D - blood</subject><issn>1530-891X</issn><issn>1934-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kctOwzAURC0EorxW7JElljTgV2Jn6QYnjQhx5KTALspTogJaErrgO_hhXNGyurM4MyPdAeASo1uGXXGnMuxhxtCtNgfgBPuUOYQhemi1S5EjfPwyAafjuESIIB-LYzAhXDCfCn4CfnJlFo8wUU8qyaEOYRjPjJ4lMi9gZPRzMYehDAptHEKnUOeF0pnRhYqUidMplOk9NCpQmSWg5eInuVU2J10EiZJm54YPMssknMEkjraeOIWZLGKVFjl8jm2JDU22_lQ_ynNw1FdvY3exu2dgEaoimDuJjuJAJk5DMf9yeO_zxnUbt6qRjzzCcC164mHCeN8Kt6uZ6_e08irOPOJ1hNYt8-vWa9qOe4RSegau_3LXw-pz041f5XK1GT5sZYkFF9wlFGFL3fxRzbAax6Hry_Xw-l4N3yVG5XaAcj9AqY2lr3aZm_q9a__Z_cfpL7fac54</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Arslan, Muyesser Sayki</creator><creator>Sahin, Mustafa</creator><creator>Karakose, Melia</creator><creator>Tutal, Esra</creator><creator>Topaloglu, Oya</creator><creator>Ucan, Bekir</creator><creator>Demirci, Taner</creator><creator>Caliskan, Mustafa</creator><creator>Ozdemir, Seyda</creator><creator>Ozbek, Mustafa</creator><creator>Cakal, Erman</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201703</creationdate><title>SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA</title><author>Arslan, Muyesser Sayki ; Sahin, Mustafa ; Karakose, Melia ; Tutal, Esra ; Topaloglu, Oya ; Ucan, Bekir ; Demirci, Taner ; Caliskan, Mustafa ; Ozdemir, Seyda ; Ozbek, Mustafa ; Cakal, Erman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-7f97c55c5ab0906241b8f261247fd85eb459f3a6a74626e23bd49bd6cde762333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Amino Acids - blood</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomarkers, Tumor - blood</topic><topic>Bone Density</topic><topic>Cabergoline</topic><topic>Cross-Sectional Studies</topic><topic>Ergolines - therapeutic use</topic><topic>Female</topic><topic>Fibroblast Growth Factors - blood</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Osteocalcin - blood</topic><topic>Osteoprotegerin - blood</topic><topic>Pituitary Neoplasms - blood</topic><topic>Pituitary Neoplasms - drug therapy</topic><topic>Prolactinoma - blood</topic><topic>Prolactinoma - drug therapy</topic><topic>Prospective Studies</topic><topic>RANK Ligand - blood</topic><topic>Receptor Activator of Nuclear Factor-kappa B - blood</topic><topic>Vitamin D - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arslan, Muyesser Sayki</creatorcontrib><creatorcontrib>Sahin, Mustafa</creatorcontrib><creatorcontrib>Karakose, Melia</creatorcontrib><creatorcontrib>Tutal, Esra</creatorcontrib><creatorcontrib>Topaloglu, Oya</creatorcontrib><creatorcontrib>Ucan, Bekir</creatorcontrib><creatorcontrib>Demirci, Taner</creatorcontrib><creatorcontrib>Caliskan, Mustafa</creatorcontrib><creatorcontrib>Ozdemir, Seyda</creatorcontrib><creatorcontrib>Ozbek, Mustafa</creatorcontrib><creatorcontrib>Cakal, Erman</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Endocrine practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arslan, Muyesser Sayki</au><au>Sahin, Mustafa</au><au>Karakose, Melia</au><au>Tutal, Esra</au><au>Topaloglu, Oya</au><au>Ucan, Bekir</au><au>Demirci, Taner</au><au>Caliskan, Mustafa</au><au>Ozdemir, Seyda</au><au>Ozbek, Mustafa</au><au>Cakal, Erman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA</atitle><jtitle>Endocrine practice</jtitle><addtitle>Endocr Pract</addtitle><date>2017-03</date><risdate>2017</risdate><volume>23</volume><issue>3</issue><spage>266</spage><epage>270</epage><pages>266-270</pages><issn>1530-891X</issn><eissn>1934-2403</eissn><abstract>The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear κB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to pituitary prolactinoma.
We recruited 46 premenopausal female patients with prolactinoma and age and sex-matched healthy controls (Group 3, n = 20) for this cross-sectional study. Prolactinoma patients were divided into 2 groups as patients newly diagnosed (Group 1, n = 26) and those under cabergoline treatment (Group 2, n = 20). Anthropometric and metabolic variables; hormonal profiles; and osteocalcin, deoxypyridinoline (DOP), and bone mineral density measurements were performed for all participants. FGF-23, OPG, and RANKL levels were analyzed in all groups.
FGF-23, OPG, calcium, phosphorus, and parathormone levels were similar between all groups despite significantly higher levels in the control group in terms of vitamin D and RANKL levels than in patients. Bone loss was found more in Group 2, particularly observed in Z scores of femur and spinal bone (P<.05). Correlation analysis revealed a negative correlation between FGF-23 and femur neck T score (r = -0.0433, P = .05) in patients with active prolactinoma. A positive correlation was also observed between parameters of DOP and OPG (r = 0.673, P = .02). In patients with remission there were a negative correlation between prolactin and luteinizing hormone (r = -600, P = .08). Additionally, a negative correlation was found between osteocalcin and osteoprotegerin in patients in remission (r = -0.73, P = .01).
Our data indicated that FGF-23 and OPG levels do not play a critical role on the development of bone decrease in patients with hyperprolactinemia. However, further prospective studies in larger numbers of participants should be designed to clarify this issue.
BFP = body fat percentage BMD = bone mineral density BMI = body mass index CV = coefficient of variation DOP = deoxypyridinoline ELISA = enzyme-linked immunosorbent assay FGF-23 = fibroblast growth factor-23 HOMA-IR = homeostatic model assessment of insulin resistance OPG = osteoprotegerin RANKL = receptor activator nuclear κB ligand.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>27849387</pmid><doi>10.4158/EP161440.OR</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1530-891X |
| ispartof | Endocrine practice, 2017-03, Vol.23 (3), p.266-270 |
| issn | 1530-891X 1934-2403 |
| language | eng |
| recordid | cdi_proquest_journals_1878752301 |
| source | MEDLINE; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Adult Amino Acids - blood Antineoplastic Agents - therapeutic use Biomarkers, Tumor - blood Bone Density Cabergoline Cross-Sectional Studies Ergolines - therapeutic use Female Fibroblast Growth Factors - blood Humans Middle Aged Osteocalcin - blood Osteoprotegerin - blood Pituitary Neoplasms - blood Pituitary Neoplasms - drug therapy Prolactinoma - blood Prolactinoma - drug therapy Prospective Studies RANK Ligand - blood Receptor Activator of Nuclear Factor-kappa B - blood Vitamin D - blood |
| title | SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T01%3A40%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SERUM%20LEVELS%20OF%20FIBROBLAST%20GROWTH%20FACTOR-23,%20OSTEOPROTEGERIN,%20AND%20RECEPTOR%20ACTIVATOR%20OF%20NUCLEAR%20FACTOR%20KAPPA%20B%20LIGAND%20IN%20PATIENTS%20WITH%20PROLACTINOMA&rft.jtitle=Endocrine%20practice&rft.au=Arslan,%20Muyesser%20Sayki&rft.date=2017-03&rft.volume=23&rft.issue=3&rft.spage=266&rft.epage=270&rft.pages=266-270&rft.issn=1530-891X&rft.eissn=1934-2403&rft_id=info:doi/10.4158/EP161440.OR&rft_dat=%3Cproquest_cross%3E4320980475%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1878752301&rft_id=info:pmid/27849387&rfr_iscdi=true |